ATE114160T1 - Immunogenische zusammensetzungen gegen gastrin- peptide. - Google Patents

Immunogenische zusammensetzungen gegen gastrin- peptide.

Info

Publication number
ATE114160T1
ATE114160T1 AT90300456T AT90300456T ATE114160T1 AT E114160 T1 ATE114160 T1 AT E114160T1 AT 90300456 T AT90300456 T AT 90300456T AT 90300456 T AT90300456 T AT 90300456T AT E114160 T1 ATE114160 T1 AT E114160T1
Authority
AT
Austria
Prior art keywords
immunogenic compositions
disclosed
compositions against
compositions
treatment
Prior art date
Application number
AT90300456T
Other languages
English (en)
Inventor
Philip C Gevas
Stephen Grimes
Stephen L Karr Jr
Richard L Littenberg
Original Assignee
Aphton Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/301,353 external-priority patent/US5023077A/en
Application filed by Aphton Corp filed Critical Aphton Corp
Application granted granted Critical
Publication of ATE114160T1 publication Critical patent/ATE114160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90300456T 1989-01-24 1990-01-17 Immunogenische zusammensetzungen gegen gastrin- peptide. ATE114160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/301,353 US5023077A (en) 1989-01-24 1989-01-24 Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US35119389A 1989-05-12 1989-05-12

Publications (1)

Publication Number Publication Date
ATE114160T1 true ATE114160T1 (de) 1994-12-15

Family

ID=26972322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90300456T ATE114160T1 (de) 1989-01-24 1990-01-17 Immunogenische zusammensetzungen gegen gastrin- peptide.

Country Status (12)

Country Link
US (3) US5607676A (de)
EP (1) EP0380230B1 (de)
JP (1) JP2526418B2 (de)
AT (1) ATE114160T1 (de)
AU (1) AU645967B2 (de)
CA (1) CA2045594C (de)
DE (1) DE69014137T2 (de)
DK (1) DK0380230T3 (de)
ES (1) ES2063912T3 (de)
IE (1) IE66267B1 (de)
PT (1) PT92938B (de)
WO (1) WO1990008774A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861510B1 (en) * 1989-01-24 2005-03-01 Aphton Corporation Immunogenic compositions against gastrin peptides
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
ES2063912T3 (es) * 1989-01-24 1995-01-16 Aphton Corp Composiciones inmunogenicas frente a peptidos de gastrina.
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
GB9406974D0 (en) * 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
ATE505202T1 (de) * 1996-02-08 2011-04-15 Cancer Advances Inc Immunologische methoden zur behandlung von gastrointestinalem krebs
US6072086A (en) * 1996-04-12 2000-06-06 Intergen Company Method and composition for controlling formaldehyde fixation by delayed quenching
US6982249B1 (en) 1997-04-23 2006-01-03 The Regents Of The University Of Michigan Bradykinin analogs as selective inhibitors of cell activation
EP1019070A4 (de) * 1997-04-23 2001-05-16 Univ Michigan Bradykinin analoge als selektive inhibitoren der zellaktivierung
CA2287872C (en) * 1997-05-12 2010-07-27 Aphton Corporation Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
US20030068326A1 (en) * 1998-05-15 2003-04-10 Aphton Corporation Method for the treatment of gastroesophageal reflux disease
AU758955C (en) * 1998-05-15 2004-09-30 Cancer Advances, Inc. Method for the treatment of gastroesophageal reflux disease
CA2328501A1 (en) * 1998-05-15 1999-11-25 Aphton Corporation Prevention and treatment of hypergastrinemia
JP2002515457A (ja) * 1998-05-15 2002-05-28 アフトン コーポレーション 腫瘍治療のための併用療法
EP1579863A3 (de) * 1998-05-15 2008-03-19 Receptor Biologix, Inc. Kombinationstherapie mit Anti-G17 Gastrin Antikörper zur Behandlung von Tumoren
EP1897556A1 (de) * 1998-05-15 2008-03-12 Receptor Biologix, Inc. Vorbeugung und Behandlung von Hypergastrinämie
DE69916273T2 (de) * 1998-06-18 2005-05-19 Vecta Ltd. Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002326356A1 (en) * 2001-07-09 2003-01-29 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
MXPA05004202A (es) * 2002-10-22 2005-09-20 Waratah Pharmaceuticals Inc Tratamiento de la diabetes.
US20080096824A1 (en) * 2003-02-28 2008-04-24 Shigemi Matsuyama Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
CN1997669A (zh) * 2004-03-29 2007-07-11 受体生物技术公司 抗胃泌素激素单克隆抗体
EP1794586B1 (de) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoklonale antikörper gegen progastrin
GB201121571D0 (en) * 2011-12-15 2012-01-25 Astrimmune Ltd Compounds and uses thereof
CN109806387B (zh) 2012-07-13 2022-03-04 S-目标疗法有限公司 免疫调节疫苗
PL2999485T3 (pl) * 2013-05-21 2018-07-31 Tyg Oncology Ltd. Kompozycja immunogenna peptydów gastrynowych
KR102772810B1 (ko) 2017-06-15 2025-02-28 캔서 어드밴시스 아이엔씨 종양 및 암에 대한 체액성 및 세포 면역을 유도하기 위한 조성물 및 방법
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
US20230398196A1 (en) * 2020-11-06 2023-12-14 Cancer Advances Inc. Compositions and methods for enhancing t cell penetration of tumors and cancers
CN115639360B (zh) * 2021-07-19 2025-05-13 武汉市朗典精医生物科技有限公司 制备前体胃泌素(pg80)抗体及建立clia检测pg80试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932242A (en) * 1957-11-21 1976-01-13 Bartley Charles E Solid propellant with butyl rubber binder
DE2256445C3 (de) * 1972-11-17 1981-11-05 Hoechst Ag, 6000 Frankfurt Heptapeptide, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
SU1414392A1 (ru) * 1982-12-29 1988-08-07 Всесоюзный кардиологический научный центр АМН СССР Противо звенное средство
FR2575164B1 (fr) * 1984-12-20 1987-03-20 Sanofi Sa Esters de tri- et tetrapeptides inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant
ES2063912T3 (es) * 1989-01-24 1995-01-16 Aphton Corp Composiciones inmunogenicas frente a peptidos de gastrina.
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US5468494A (en) * 1993-11-12 1995-11-21 Aphton Corp. Immunogenic compositions against human gastrin 17

Also Published As

Publication number Publication date
DK0380230T3 (da) 1995-01-16
WO1990008774A1 (en) 1990-08-09
IE900250L (en) 1990-07-24
US5609870A (en) 1997-03-11
US5785970A (en) 1998-07-28
DE69014137T2 (de) 1995-06-08
US5607676A (en) 1997-03-04
AU5082090A (en) 1990-08-24
JPH04503072A (ja) 1992-06-04
AU645967B2 (en) 1994-02-03
CA2045594C (en) 2002-08-13
CA2045594A1 (en) 1990-07-25
EP0380230B1 (de) 1994-11-17
PT92938A (pt) 1990-07-31
ES2063912T3 (es) 1995-01-16
JP2526418B2 (ja) 1996-08-21
PT92938B (pt) 1996-09-30
IE66267B1 (en) 1995-12-27
EP0380230A2 (de) 1990-08-01
EP0380230A3 (de) 1991-06-26
DE69014137D1 (de) 1994-12-22

Similar Documents

Publication Publication Date Title
DE69014137D1 (de) Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
RU93048636A (ru) 7-/замещенные/-8-/замещенные/-9-/замещенные амино/-6-диметил-6-дезокситетрациклины, промежуточные соединения, способы получения соединений, способ профилактики и лечения и фармацевтическая композиция
ATE60697T1 (de) Verfahren zur bekaempfung von pilzen.
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69303803D1 (de) Behandlungsmethode zur Bodenverfestigung
DE69432513D1 (de) Gangliosid-klh-konjugatimastoffe mit qs-21
KR890701107A (ko) 알쯔하이머 병 치료용 화합물들
DE69330899D1 (de) Verwendung von Bismuth-213 Konjugate zur Behandlung von Mikrometastasen
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE3854121D1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
FI924363A7 (fi) Menetelmä pehmytkudoskasvainten hoitamiseksi ja/tai diagnosoimiseksi
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DE3874638D1 (de) Behandlungsapparat und -verfahren.
BR9007738A (pt) Metodo de tratamento de couros
FI935428A7 (fi) Maaperän käsittelykoostumus ja menetelmä sen levittämiseksi
MX9200755A (es) Tratamiento de carcinoma pulmonar de celulas no pequeñas.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE3873848D1 (de) Behandlungsapparat und -verfahren.
DE3878137D1 (de) Behandlungsmethode zur bodenstabilisierung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee